Maiva Pharma, the Benguluru based pure play injectables Contract Development and Manufacturing Organization (CDMO) catering to US market, has raised Rs 1,000 crores in primary and secondary funding from a fund managed by Morgan Stanley Private Equity Asia and India Life Sciences Fund - IV (InvAscent), for a controlling stake from existing investors and infused primary capital in the company.Morgan Stanley PE Asia and India Life Sciences Fund are investing almost equally, total stake with both funds combined will be over 60% post primary investment, the company told ET.This is Maiva’s first private equity fundraise.

迈瓦制药（Maiva Pharma）是一家总部位于本古鲁鲁的面向美国市场的纯注射用合同开发和制造组织（CDMO），已从摩根士丹利亚洲私人股本和印度生命科学基金（InvAscent）管理的基金中筹集了1000亿卢比的一级和二级资金，用于现有投资者的控股权，并注入了公司的主要资本。摩根士丹利私募股权亚洲基金和印度生命科学基金的投资几乎持平，两支基金的总股本在初次投资后将超过60%，该公司告诉ET。这是Maiva的首次私募股权融资。

Few existing high networth individual (HNI) investors will be exiting.The company plans to use the proceeds to set up a new manufacturing plant near Hosur, Karnataka, with capabilities in sterile dosage forms including pre-filled syringes, bags, oncology and hormonal injectables.Incorporated in 1993, Maiva is expected to end FY24 with revenue of around Rs 300 crore in FY24, with business growing at over 40% YoY in revenue.The company has a US FDA, EU GMP and ANVISA approved state-of-the-art manufacturing facility located at Hosur with a strong regulatory compliance track record and sterile injectables capabilities in vials and lyophilized vials.

现有的高净值个人（HNI）投资者很少会退出。该公司计划利用所得收益在卡纳塔克邦霍苏尔附近建立一家新的制造厂，该厂具有无菌剂型的能力，包括预填充注射器、袋、肿瘤学和激素注射剂。Maiva成立于1993年，预计在2014财年结束时，其收入将达到约30亿卢比，业务收入年环比增长超过40%。该公司拥有美国FDA、欧盟GMP和ANVISA批准的最先进的生产设施，位于Hosur，拥有强大的法规遵从性记录以及瓶和冻干瓶的无菌注射剂能力。

The company has a portfolio of 75+ products for CDMO services. These products cater to around 40 customers across the US, Canada, Europe, Australia, and LATAM markets.Avendus acted as the exclusive financial advisor to Maiva and its shareholders on this transaction.“Over the last three years, Maiva has quadrupled its manufacturing capacity for US, Canada, and EU markets,' said Dr.

该公司拥有75多种CDMO服务产品组合。这些产品面向美国、加拿大、欧洲、澳大利亚和拉丁美洲市场的大约40位客户。Avendus担任Maiva及其股东在此次交易中的独家财务顾问。“在过去的三年里，玛瓦在美国、加拿大和欧盟市场的制造能力翻了两番。”

Bhaskar Krishna, managing director and CEO at Maiva Pharma.'Based on continued strong interest from customers in partnering with Maiva, we .

Maiva Pharma董事总经理兼首席执行官Bhaskar Krishna说基于客户对与Maiva合作的持续浓厚兴趣，我们。